Participant flow21

How many started, completed or left each group, period by period.

1 to 20 of 21

Period	Milestone	Group	Participants
Study Period II	STARTED	Olanzapine	105
Study Period II	STARTED	Haloperidol	20
Study Period II	STARTED	Placebo	99
Study Period II	Received at Least One Dose of Study Drug	Olanzapine	104
Study Period II	Received at Least One Dose of Study Drug	Haloperidol	20
Study Period II	Received at Least One Dose of Study Drug	Placebo	97
Study Period II	COMPLETED	Olanzapine	72
Study Period II	COMPLETED	Haloperidol	8
Study Period II	COMPLETED	Placebo	52
Study Period II	NOT COMPLETED	Olanzapine	33
Study Period II	NOT COMPLETED	Haloperidol	12
Study Period II	NOT COMPLETED	Placebo	47
Study Period III	STARTED	Olanzapine	72
Study Period III	STARTED	Haloperidol	8
Study Period III	STARTED	Placebo	52
Study Period III	COMPLETED	Olanzapine	59
Study Period III	COMPLETED	Haloperidol	7
Study Period III	COMPLETED	Placebo	42
Study Period III	NOT COMPLETED	Olanzapine	13
Study Period III	NOT COMPLETED	Haloperidol	1

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00129220/flow